Oncolytics Biotech Inc. (ONCY)
After hours:
| Previous Close | 1.0400 |
| Open | 1.0300 |
| Bid | 1.0000 x 200 |
| Ask | 1.0700 x 200 |
| Day's Range | 1.0200 - 1.0600 |
| 52 Week Range | 0.8800 - 3.3900 |
| Volume | |
| Avg. Volume | 383,691 |
| Market Cap | 77.682M |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3000 |
| Earnings Date | May 03, 2024 - May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.80 |
- Baystreet
Stocks in play: Oncolytics Biotech® Inc.
Announced the submission of a Type C meeting request to the FDA. This meeting aims to discuss the Company's ...
PR NewswireOncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to announce the submission of a Type C meeting request to the FDA. This meeting aims to discuss the Company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC).
CNW GroupOncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that President and Chief Executive Officer Dr. Matt Coffey will participate in the Viral Approaches in Oncology panel at Canaccord Genuity's Horizons in Oncology Virtual Conference, which is taking place on April 15, 2024. Additional details on the panel presentation can be found below.
